<DOC>
	<DOCNO>NCT01240460</DOCNO>
	<brief_summary>The purpose study measure effect study drug XL765 ( SAR245409 ) study drug XL147 ( SAR245408 ) tumor tissue subject recurrent glioblastoma ( GB ) candidate surgical resection . XL765 ( SAR245409 ) XL147 ( SAR245408 ) , two investigational agent examine study , XL147 ( SAR245408 ) potent inhibitor PI3 Kinase ( PI3K ) XL765 ( SAR245409 ) dual PI3K mTOR inhibitor . In preclinical study , inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell .</brief_summary>
	<brief_title>Exploratory Study XL765 ( SAR245409 ) XL147 ( SAR245408 ) Subjects With Recurrent Glioblastoma Who Are Candidates Surgical Resection</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<criteria>1 . The subject histologically confirm diagnosis primary GB subject receive prior treatment , include radiation and/or chemotherapy , undergo second surgical resection . 2 . The subject available archival tumor tissue time initial diagnosis GB designate central laboratory analysis . 3 . The subject ≥ 18 year old . 4 . The subject Karnofsky performance status ( KPS ) ≥ 60 % . 5 . The subject adequate organ marrow function . 6 . The subject adequate fasting plasma glucose level glycosylated hemoglobin level . 7 . The subject capable understanding comply protocol requirement sign informed consent document . 8 . Sexually active subject ( men woman ) must agree use medicallyaccepted barrier method contraception course study 3 month last dose study drug , even oral contraceptive also use . All subject reproductive potential must agree use barrier method second method birth control . 9 . Women childbearing potential must negative pregnancy test screening . 1 . The subject confirm secondary GB ( ie , pathologyconfirmed lowergrade glioma subsequently recur high grade glioma ) . 2 . The subject 's tumor predominance WHO Grade IV oligoastrocytoma . 3 . The subject receive radiation therapy GB within 12 week ( ≤ 84 day ) first dose study drug treatment . 4 . The subject receive specific type anticancer therapy ( discussed treat physician ) 5 . The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 Grade ≤ 1 AEs due surgery , radiation , antineoplastic agent , investigational drug , medication administer screening ( except Grade 2 alopecia Grade 2 lymphocytopenia ) . 6 . The subject receive &gt; 1 mg/day warfarin ( equivalent coumarin derivative ) unable switch low molecular weight heparin within 14 day first dose study drug . 7 . The subject receive enzymeinducing antiepileptic agent ( EIAED ; eg , carbamazepine , phenytoin , phenobarbital , primidone ) valproic acid unable convert EIAED antiseizure agent within 14 day first dose study drug . 8 . The subject uncontrolled intercurrent illness include , limited : Ongoing active infection Hypertension ( consistent blood pressure reading &gt; 140 mmHg systolic &gt; 100 mmHg diastolic ) despite optimal treatment Significant cardiac arrhythmia , recent history serious disease , either symptomatic congestive heart failure unstable angina pectoris within 3 month , follow event within 6 month : myocardial infarction , stroke , transient ischemic attack . Inherited acquire bleed diathesis 9 . The subject baseline correct QT interval ( QTc ) &gt; 460 ms. 10 . The subject unable undergo repeat magnetic resonance imaging ( MRI ) scan reason ( eg , cardiac pacemaker ferromagnetic metal implant ) . 11 . The subject know positive human immunodeficiency virus ( HIV ) . Note : HIV test require eligibility . 12 . The subject impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study treatment ( eg , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) . 13 . The subject pregnant breastfeeding . 14 . The subject previously identify allergy hypersensitivity component study treatment formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>